

Initial Prior Authorization with Quantity Limit Ivermectin (Oral)

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
|-------------------------------|--------------|
| Stromectol | ivermectin |
| Ivermectin (all other brands) | ivermectin |

Indications

FDA-Approved Indications

Stromectol and ivermectin tablets are indicated for the treatment of the following infections:

Strongyloidiasis of the intestinal tract

Stromectol and ivermectin tablets are indicated for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*.

Onchocerciasis

Stromectol and ivermectin tablets are indicated for the treatment of onchocerciasis due to the nematode parasite *Onchocerca volvulus*.

Stromectol and ivermectin tablets have no activity against adult *Onchocerca volvulus* parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these

| |
|---------------------|
| Reference number(s) |
| 4909-C |

nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.

Coverage Criteria

Coronavirus Disease 2019 (COVID-19)

Authorization may be granted when the requested drug is NOT being prescribed for the prevention or treatment of coronavirus disease 2019 (COVID-19).

Quantity Limits Apply

The duration of 75 days is used for a 90-day fill period.

| Drug | 3 Month Limit |
|------------------------------|---------------------|
| Stromectol (ivermectin) 3 mg | 9 tablets / 75 days |
| ivermectin 6 mg | 5 tablets / 75 days |

Duration of Approval (DOA)

- 4909-C: DOA: 3 months

References

1. Stromectol [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; May 2022.
2. Ivermectin [package insert]. East Windsor, NJ: Advagen Pharma Ltd.; August 2024.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 22, 2024.
4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/22/2024).
5. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed November 22, 2024.
6. Therapeutics and COVID-19: living guideline, 10 November 2023. Geneva: World Health Organization; 2023 (WHO-2019-nCoV-therapeutics-2023.2). Accessed November 26, 2024.

| Reference number(s) |
|---------------------|
| 4909-C |

7. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat 3(46). January 2021.